The Health Ministry recently commemorated eight years of the National Viral Hepatitis Control Programme (NVHCP), a landmark public health initiative launched in 2016 to combat the rising burden of viral hepatitis in India. The programme represents a comprehensive approach to addressing hepatitis B and C, two potentially life-threatening infections that affect millions of Indians.
Understanding Viral Hepatitis
Viral hepatitis refers to inflammation of the liver caused by specific viruses, primarily hepatitis A, B, C, D, and E. Among these, hepatitis B and C are particularly concerning as they can become chronic conditions, potentially leading to liver cirrhosis, liver cancer, and liver failure. India has one of the highest burdens of hepatitis B and C globally, with an estimated 40 million people living with chronic hepatitis B and 6-12 million with hepatitis C.
These infections spread through contact with infected blood, contaminated medical equipment, unsafe injection practices, and from mother to child during childbirth. Unlike hepatitis A and E, which typically cause acute infections, hepatitis B and C can persist for years without symptoms, silently damaging the liver.
Programme Objectives and Strategies
The NVHCP was designed with multiple objectives to reduce morbidity and mortality from viral hepatitis. The programme focuses on prevention through vaccination, early diagnosis through widespread screening, and ensuring access to affordable treatment for those infected.
Key strategies include:
- Strengthening laboratory networks for hepatitis testing across district hospitals
- Providing free screening and diagnostic services at government facilities
- Ensuring availability of antiviral medications at subsidized rates
- Training healthcare workers in hepatitis management
- Raising public awareness about prevention and transmission
- Integrating hepatitis services with existing health programmes
- Establishing dedicated hepatitis clinics in medical colleges and district hospitals
Major Achievements
Over the past eight years, the NVHCP has made substantial progress in expanding access to hepatitis care. The programme has established testing facilities in hundreds of districts, enabling early detection in previously underserved areas. Millions of people have been screened for hepatitis B and C, with those testing positive being linked to treatment services.
The programme has also negotiated significantly reduced prices for antiviral medications. Direct-acting antiviral drugs for hepatitis C, which once cost lakhs of rupees, are now available at a fraction of the original price, making cure accessible to economically disadvantaged patients. Similarly, medications for managing chronic hepatitis B have become more affordable and widely available.
Vaccination coverage has expanded considerably, with hepatitis B vaccine included in the Universal Immunization Programme. Newborns now receive the birth dose of hepatitis B vaccine, protecting them from infection during the vulnerable early months of life.
Integration with Other Health Initiatives
The NVHCP functions in coordination with other national health programmes, creating synergies that improve overall outcomes. Integration with the National AIDS Control Programme has been particularly effective, as both programmes share common transmission routes and target populations. Facilities testing for HIV also offer hepatitis B and C screening, maximizing reach and efficiency.
Similarly, collaboration with maternal and child health programmes ensures that pregnant women are screened for hepatitis B, preventing mother-to-child transmission through timely intervention. Blood safety initiatives have also reduced transmission through contaminated blood products.
Remaining Challenges
Despite notable progress, significant challenges remain in eliminating viral hepatitis as a public health threat. Many people living with chronic hepatitis remain undiagnosed due to the asymptomatic nature of early infection. Awareness levels in rural and remote areas need improvement, as stigma and misconceptions continue to deter people from seeking testing and treatment.
Healthcare infrastructure gaps in certain regions limit service delivery, while maintaining a steady supply of diagnostic kits and medications requires continuous effort. Additionally, reaching high-risk populations such as injection drug users, prisoners, and healthcare workers demands targeted interventions.
The Road Ahead
As the programme enters its ninth year, focus areas include scaling up screening initiatives, eliminating remaining gaps in treatment access, and strengthening surveillance systems to monitor disease trends. The Health Ministry has aligned the NVHCP with the World Health Organization's goal of eliminating viral hepatitis as a public health threat by 2030, requiring sustained political commitment and resource allocation.
This article is for general informational purposes only and should not be considered medical advice. If you suspect you may have been exposed to hepatitis or experience symptoms of liver disease, please consult a qualified healthcare provider for proper evaluation and treatment.
